Treatment Of Overactive Bladder In Women Research Articles

Defining and Managing Overactive Bladder: Disagreement Among the Experts

To better understand experts' perceptions of the definition of overactive bladder (OAB) and the evaluation and treatment of OAB in women. OAB has been defined by the International Continence Society as "urinary urgency, with or without urge urinary incontinence, usually with frequency and nocturia." Under the current definition, people with very different clinical conditions are included under the OAB umbrella. In the present study, 12 interviews with leading urologic, gynecologic, and geriatric practitioners in urinary incontinence and OAB were performed. Questions were asked about their perception and agreement with the current definition of OAB. The interviews were audiotaped and transcribed verbatim. The grounded theory method was used to analyze the data. Overall, a great amount of variability was found in the definition and management of OAB. Four categories of definitions were derived from the qualitative analysis: the current OAB definition is adequate, OAB is a constellation of symptoms, OAB should include the fear of leakage, and OAB is a marketing term. Although some consensus has been reached on the evaluation, several areas have demonstrated disagreement over elements of the evaluation. Experts also believed that OAB is a chronic condition, with symptom variability, and has no cure. Managing patient expectations is essential, because OAB is challenging to treat. A focus was placed on behavioral therapy. The experts disagreed over the definition and workup of OAB. However, the experts agreed that OAB is a chronic condition with a low likelihood of cure.

The efficacy of posterior tibial nerve stimulation for the treatment of overactive bladder in women: a systematic review

Posterior tibial nerve stimulation (PTNS) is a percutaneous method of peripheral, sacral neuromodulation. Its current use is limited; however, published data suggest PTNS may be an effective treatment for overactive bladder (OAB). We systematically reviewed the literature on PTNS for treatment of idiopathic OAB in women from January 2000 to August 2010 published in English in MEDLINE/PubMed, Embase, and Cochrane databases. We included randomized controlled trials or observational studies reporting objective outcome measures with the use of either the Urgent PC or Stoller Afferent Nerve Stimulator (SANS) for PTNS. Studies were considered "good quality" if results from objective measures were provided for ≥20 women, results distinguished between type of OAB symptom, and data were reported separately for female subjects. Of the 136 identified articles, 17 met inclusion criteria for data abstraction; 4 of the 17 studies met our criteria for good quality and reported success rates of 54-93 %. Recurrent limitations in the literature were pooling of results for male and female subjects and lack of differentiation in the data on specific symptoms of OAB treated. Short-term follow-up and infrequent use of a control arm were also noted shortcomings of reviewed studies. Limited high quality data exist on PTNS for OAB in women. Although initial studies have demonstrated promise, more comprehensive evaluation of PTNS is needed to support its universal use for the treatment of OAB in women.

Efficacy and adverse events of sacral nerve stimulation for overactive bladder: A systematic review

To systematically review the literature regarding efficacy and adverse events of sacral nerve stimulation (SNS) via the InterStim device for treatment of women with refractory overactive bladder (OAB). We searched MEDLINE, Embase, Web of Science, and the Cochrane Collaboration databases from 1980 to September 2008. All English studies reporting on efficacy or adverse events of SNS for the treatment of refractory OAB were considered. Only studies where 30 or more women received the complete therapy (implanted lead and generator) were included. The quality of the studies (good, fair, or poor) was assessed based on predefined criteria. Seven studies were designated "good" regarding efficacy of SNS for OAB. Multiple authors reported results from the same cohort of patients. In this instance, the highest quality study was chosen, leaving three independent studies regarding efficacy. In these studies, incontinent episodes per day and pad usage significantly improved after SNS therapy. Six studies were designated "good" regarding adverse events. Using tined leads, surgical revision rates ranged from 3% to 16%. Six percent of patients were explanted due to lack of efficacy and 5-11% of patients were explanted due to infection. Based on observational data, SNS appears effective for treatment of OAB in women. Adverse event rates with tined leads are lower than previously published estimates using non-tined leads. High-quality studies are needed to confirm our findings and to provide additional data regarding reprogramming, quality of life, and efficacy when compared to other therapies.